1. Home
  2. Author
  3. Morrison RD

Morrison RD

References (2)

Title : Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012 - Melancon_2012_Bioorg.Med.Chem.Lett_22_1044
Author(s) : Melancon BJ , Lamers AP , Bridges TM , Sulikowski GA , Utley TJ , Sheffler DJ , Noetzel MJ , Morrison RD , Daniels JS , Niswender CM , Jones CK , Conn PJ , Lindsley CW , Wood MR
Ref : Bioorganic & Medicinal Chemistry Lett , 22 :1044 , 2012
Abstract : Melancon_2012_Bioorg.Med.Chem.Lett_22_1044
ESTHER : Melancon_2012_Bioorg.Med.Chem.Lett_22_1044
PubMedSearch : Melancon_2012_Bioorg.Med.Chem.Lett_22_1044
PubMedID: 22197142

Title : The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease - Jones_2012_J.Pharmacol.Exp.Ther_340_404
Author(s) : Jones CK , Bubser M , Thompson AD , Dickerson JW , Turle-Lorenzo N , Amalric M , Blobaum AL , Bridges TM , Morrison RD , Jadhav S , Engers DW , Italiano K , Bode J , Daniels JS , Lindsley CW , Hopkins CR , Conn PJ , Niswender CM
Ref : Journal of Pharmacology & Experimental Therapeutics , 340 :404 , 2012
Abstract : Jones_2012_J.Pharmacol.Exp.Ther_340_404
ESTHER : Jones_2012_J.Pharmacol.Exp.Ther_340_404
PubMedSearch : Jones_2012_J.Pharmacol.Exp.Ther_340_404
PubMedID: 22088953